348 related articles for article (PubMed ID: 26763072)
1. Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing.
Tan DQ; Zhang L; Ohba K; Ye M; Ichiyama K; Yamamoto N
Eur J Immunol; 2016 Apr; 46(4):919-28. PubMed ID: 26763072
[TBL] [Abstract][Full Text] [Related]
2. Combination of Vaccine-Strain Measles and Mumps Viruses Enhances Oncolytic Activity against Human Solid Malignancies.
Son HA; Zhang L; Cuong BK; Van Tong H; Cuong LD; Hang NT; Nhung HTM; Yamamoto N; Toan NL
Cancer Invest; 2018 Feb; 36(2):106-117. PubMed ID: 29485292
[TBL] [Abstract][Full Text] [Related]
3. Use of attenuated paramyxoviruses for cancer therapy.
Lech PJ; Russell SJ
Expert Rev Vaccines; 2010 Nov; 9(11):1275-302. PubMed ID: 21087107
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic virotherapy of breast cancer.
Hartkopf AD; Fehm T; Wallwiener D; Lauer UM
Gynecol Oncol; 2011 Oct; 123(1):164-71. PubMed ID: 21764108
[TBL] [Abstract][Full Text] [Related]
5. Chemovirotherapeutic Treatment Using Camptothecin Enhances Oncolytic Measles Virus-Mediated Killing of Breast Cancer Cells.
Tai CJ; Liu CH; Pan YC; Wong SH; Tai CJ; Richardson CD; Lin LT
Sci Rep; 2019 May; 9(1):6767. PubMed ID: 31043633
[TBL] [Abstract][Full Text] [Related]
6. Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus.
Ellerhoff TP; Berchtold S; Venturelli S; Burkard M; Smirnow I; Wulff T; Lauer UM
Int J Oncol; 2016 Nov; 49(5):1931-1944. PubMed ID: 27601235
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.
Saito K; Shirasawa H; Isegawa N; Shiiba M; Uzawa K; Tanzawa H
Oral Oncol; 2009 Dec; 45(12):1021-7. PubMed ID: 19833547
[TBL] [Abstract][Full Text] [Related]
8. Enhanced killing of therapy-induced senescent tumor cells by oncolytic measles vaccine viruses.
Weiland T; Lampe J; Essmann F; Venturelli S; Berger A; Bossow S; Berchtold S; Schulze-Osthoff K; Lauer UM; Bitzer M
Int J Cancer; 2014 Jan; 134(1):235-43. PubMed ID: 23797800
[TBL] [Abstract][Full Text] [Related]
9. Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.
Jing Y; Chavez V; Ban Y; Acquavella N; El-Ashry D; Pronin A; Chen X; Merchan JR
Mol Cancer Res; 2017 Oct; 15(10):1410-1420. PubMed ID: 28679779
[TBL] [Abstract][Full Text] [Related]
10. [Oncolytic Paramyxoviruses: Mechanism of Action, Preclinical and Clinical Studies].
Matveeva OV; Kochneva GV; Zainutdinov SS; Ilyinskaya GV; Chumakov PM
Mol Biol (Mosk); 2018; 52(3):360-379. PubMed ID: 29989571
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
Achard C; Boisgerault N; Delaunay T; Roulois D; Nedellec S; Royer PJ; Pain M; Combredet C; Mesel-Lemoine M; Cellerin L; Magnan A; Tangy F; Grégoire M; Fonteneau JF
Oncotarget; 2015 Dec; 6(42):44892-904. PubMed ID: 26539644
[TBL] [Abstract][Full Text] [Related]
13. Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-oncolytic virus.
Yoo JY; Ryu J; Gao R; Yaguchi T; Kaul SC; Wadhwa R; Yun CO
J Gene Med; 2010 Jul; 12(7):586-95. PubMed ID: 20603860
[TBL] [Abstract][Full Text] [Related]
14. Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S; Bailey K; Fielding A
Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Virotherapy Blockade by Microglia and Macrophages Requires STAT1/3.
Delwar ZM; Kuo Y; Wen YH; Rennie PS; Jia W
Cancer Res; 2018 Feb; 78(3):718-730. PubMed ID: 29118089
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulation in Oncolytic Measles Virotherapy.
Dietz L; Engeland CE
Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between oncolytic viruses and autophagy in cancer therapy.
Jin KT; Tao XH; Fan YB; Wang SB
Biomed Pharmacother; 2021 Feb; 134():110932. PubMed ID: 33370632
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword.
Blitz SE; Kappel AD; Gessler FA; Klinger NV; Arnaout O; Lu Y; Peruzzi PP; Smith TR; Chiocca EA; Friedman GK; Bernstock JD
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163730
[TBL] [Abstract][Full Text] [Related]
19. An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis.
Lampe J; Bossow S; Weiland T; Smirnow I; Lehmann R; Neubert W; Bitzer M; Lauer UM
Gene Ther; 2013 Nov; 20(11):1033-41. PubMed ID: 23719065
[TBL] [Abstract][Full Text] [Related]
20. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
Hofman L; Lawler SE; Lamfers MLM
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
